Pacific Biosciences of California, Inc. (PACB)
NASDAQ: PACB · Real-Time Price · USD
2.100
-0.010 (-0.47%)
Oct 26, 2026, 9:36 AM EDT - Market open
PACB Revenue
Pacific Biosciences of California had revenue of $39.01M in the quarter ending June 30, 2026, a decrease of -1.91%. This brings the company's total for the last twelve months to $159.27M, up 2.02% year-over-year. In the year 2025, Pacific Biosciences of California had annual revenue of $160.01M with 3.89% growth. That makes Pacific Biosciences of California the 19,160th largest company in the world by revenue and 3,021st in the United States.
Revenue (ttm)
$159.27M
Revenue Growth
+2.02%
P/S Ratio
4.12
Revenue / Employee
$328,394
Employees
485
Market Cap
652.74M
Revenue by Geography
- United States of America 69.70M 43.6%
- Europe, Middle East and Africa 44.05M 27.5%
- Asia Pacific 43.16M 27.0%
- Americas (excl. United States) 3.10M 1.9%
Fiscal year ended Dec 31, 2025 See the full PACB breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 160.01M | 5.99M | 3.89% |
| Dec 31, 2024 | 154.01M | -46.51M | -23.19% |
| Dec 31, 2023 | 200.52M | 72.22M | 56.29% |
| Dec 31, 2022 | 128.30M | -2.21M | -1.69% |
| Dec 31, 2021 | 130.51M | 51.62M | 65.43% |
| Dec 31, 2020 | 78.89M | -12.00M | -13.20% |
| Dec 31, 2019 | 90.89M | 12.27M | 15.60% |
| Dec 31, 2018 | 78.63M | -14.84M | -15.88% |
| Dec 31, 2017 | 93.47M | 2.75M | 3.04% |
| Dec 31, 2016 | 90.71M | -2.07M | -2.23% |
| Dec 31, 2015 | 92.78M | 32.19M | 53.12% |
| Dec 31, 2014 | 60.59M | 32.41M | 115.02% |
| Dec 31, 2013 | 28.18M | 2.20M | 8.46% |
| Dec 31, 2012 | 25.98M | -7.88M | -23.27% |
| Dec 31, 2011 | 33.86M | 32.19M | 1,922.88% |
| Dec 31, 2010 | 1.67M | 1.54M | 1,140.00% |
| Dec 31, 2009 | 135.00K | -766.00K | -85.02% |
| Dec 31, 2008 | 901.00K | -1.26M | -58.34% |
| Dec 31, 2007 | 2.16M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| AdaptHealth | 3.36B |
| Varex Imaging | 865.00M |
| InMode | 374.63M |
| Tactile Systems Technology | 350.31M |
| OrthoPediatrics | 252.72M |
| Cytek Biosciences | 206.71M |
| Delcath Systems | 95.42M |
| Sight Sciences | 83.38M |
PACB News
- 3 days ago - PacBio price target raised to $2.50 from $1.50 at Stephens - TheFly
- 7 days ago - PacBio announces multi-year strategic collaboration with Verily Health - TheFly
- 7 days ago - PacBio and Verily Health Announce Multi-Year Strategic Collaboration to Scale Long-Read Genomics for Biomedical AI - GlobeNewsWire
- 11 days ago - PacBio to Report Third Quarter 2026 Financial Results on November 4, 2026 - GlobeNewsWire
- 20 days ago - PacBio, TychoBio collaborate to generate full-length RNA data - TheFly
- 20 days ago - PacBio and TychoBio Collaborate to Train AI Models for Rare Disease RNA Therapeutics - GlobeNewsWire
- 27 days ago - Pacific Biosciences of California Slides: Canaccord Bus Tour presentation - Filings
- 5 weeks ago - Pacific Biosciences of California Transcript: Morgan Stanley 24th Annual Global Healthcare Conference - Transcripts